Bo-Yin Zhang

Prof. Dr. Bo-Yin Zhang


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2022 in World Neurosurgery
Verified
Journal Article
Closed access
ZLZhen-Gang Liu
Zhen-Gang Liu
FYFan Yang
Fan Yang
YZYu-Hang Zhu
Yu-Hang Zhu
GLGuang-Chen Liu
Guang-Chen Liu
QZQing-San Zhu
Qing-San Zhu
BZBo-Yin Zhang
Bo-Yin Zhang

10 January 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
FYFan Yang
Fan Yang
ZLZhengang Liu
Zhengang Liu
YZYibo Zhang
Yibo Zhang
PLPengfu Li
Pengfu Li
YZYuhang Zhu
Yuhang Zhu
BZBo-Yin Zhang
Bo-Yin Zhang
Purpose: Hypertrophic pachymeningitis associated with immunoglobulin G4-related disease (IgG4-RD) has been rarely reported, and there is little information and no clear consensus on the management of IgG4-related spinal pachymeningitis (IgG4-RSP). The present study described its possible clinical features, including the symptoms, imaging, treatment and prognosis of patients with IgG4-RSP.Methods: We report three patients who presented with progressive neurological dysfunction due to spinal cord compression. Relevant articles were searched from the PubMed, Web of Science, and Embase databases, and the resulting literature was reviewed.Results: The literature review provided a summary of 45 available cases, which included three cases from our center. Progressive worsening of neurological impairment was observed in 22 patients (48.9%). The lesions involved the thoracic spine (n=28, 62.2%), cervical spine (n=26, 57.8%), lumbar spine (n=9, 20.0%), and sacral spine (n=1, 2.2%). Furthermore, the lesions were located in the dura mater (n=18, 40.0%), epidural space (n=17, 37.8%), intradural-extramedullary space (n=9, 20.0%), and intramedullary space (n=1, 2.2%). On magnetic resonance imaging (MRI), the lesions generally appeared as striated, fusiform, or less often lobulated oval changes, with homogeneous (n=17,44.7%) and dorsal (n=15,39.5%) patterns being the most common. Thirty-five patients had homogeneous T1 gadolinium enhancement. Early surgical decompression, corticosteroid treatment, and steroid-sparing agents offered significant therapeutic advantages. A good therapeutic response to disease recurrence was observed with the medication.Conclusion: The number of reported cases of IgG4-RSP remains limited, and patients often have progressive worsening of their neurological symptoms. The features of masses identified on the MRI should be considered. The prognosis was better with decompression surgery combined with immunosuppressive therapy. Long-term corticosteroid treatment and steroid-sparing agent maintenance therapy should be ensured. A systemic examination is recommended to identify the presence of other pathologies.

7 December 2022 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
LZLiu Zhen-Gang
Liu Zhen-Gang
YFYang Fan
Yang Fan
SJShi Jingwei
Shi Jingwei
CPChang Pengyu
Chang Pengyu
YSYu Shengman
Yu Shengman
BZBo-Yin Zhang
Bo-Yin Zhang
Spinal cord injury (SCI) induced catastrophic neurological disability is currently incurable, especially in elderly patients. Due to the limited axon regeneration capacity and hostile microenvironment in the lesion site, essential neural network reconstruction remains challenging. Owing to the blood–spinal cord barrier (BSCB) created immune cells and cytokines isolation, the immune elements were incorrectly recognized as innocent bystanders during the SCI pathological process traditionally. Emerging evidence demonstrated that the central nervous system (CNS) is an “immunological quiescent” rather than “immune privileged” area, and the CNS-associated immune response played mixed roles which dedicate beneficial and detrimental contributions throughout the SCI process. Consequently, coordinating double-edged immunomodulation is vital to promote tissue repair and neurological recovery post-SCI. The comprehensive exploration and understanding of the immune landscape post-SCI are essential in establishing new avenues for further basic and clinical studies. In this context, this review summarizes the recent significant breakthroughs in key aspects of SCI-related immunomodulation, including innate and adaptive immune response, immune organ changes, and holistic immune status modification. Moreover, the currently existing immune-oriented therapies for SCI will be outlined.

1 May 1999 in Journal of Wind Engineering and Industrial Aerodynamics
Verified
Journal Article
Closed access
JSJianguo Sang
Jianguo Sang
GLGuanming Lin
Guanming Lin
BZBo-Yin Zhang
Bo-Yin Zhang

27 February 2022 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
EJErna Jia
Erna Jia
NRNa Ren
Na Ren
BGBo Guo
Bo Guo
ZCZhi Cui
Zhi Cui
BZBo-Yin Zhang
Bo-Yin Zhang
JXJinru Xue
Jinru Xue
Background: N6-methyladenosine (m6A) is the most prevalent modification in mRNA in biological processes and associated with various malignant tumor initiation and progression. The present study aimed to construct a prognostic risk model based on m6A-related genes (the downstream genes influenced by m6A modulators) for LUSC. Methods: Based on TCGA, we stratified LUSC patients with and without genetic alteration of m6A modulators into altered and unaltered groups. Using univariate Cox and Lasso regression analyses, we identified prognostic m6A-related genes to construct a prognostic risk model. We then applied a multivariate Cox proportional regression model and the survival analysis to evaluate the risk model. Moreover, we performed the Receiver operating characteristic curve to assess the efficiency of the prognostic model based on TCGA and GSE43131. We analyzed the characteristics of tumor-associated immune cell infiltration in LUSC through the CIBERSORT method. Results: Three m6A-related genes (FAM71F1, MT1E, and MYEOV) were identified as prognostic genes for LUSC. A novel prognostic risk model based on the three m6A-related genes was constructed. The multivariate Cox analysis showed that the prognostic risk model was an independent risk factor (HR = 2.44, 95% CI = 1.21~3.56, p = 0.029). Patients with a high-risk group had worse overall survival both in TCGA (p = 0.018) and GSE43131 (p = 0.00017). The 1, 2, and 3-year AUC value in TCGA was 0.662, 0.662, and 0.655, respectively; The 1, 2, and 3-year AUC value in GSE43131 was 0.724, 0.724, and 0.722, respectively. The proportion of infiltrated neutrophils in the high-risk group was higher than that in the low-risk group (p = 0.028), whereas that of resting NK cells (p = 0.002) was lower. Conclusion: A novel prognostic risk model based on three m6A-related genes for LUSC was generated in this study.

9 January 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
ZLZhen-Gang Liu
Zhen-Gang Liu
LZLai-Yang Zhou
Lai-Yang Zhou
YSYong-Quan Sun
Yong-Quan Sun
YMYi-Hang Ma
Yi-Hang Ma
CLChang-Mei Liu
Chang-Mei Liu
BZBo-Yin Zhang
Bo-Yin Zhang
Retinal ganglion cells (RGCs) generally fail to regenerate axons, resulting in irreversible vision loss after optic nerve injury. While many studies have shown that modulating specific genes can enhance RGCs survival and promote optic nerve regeneration, inducing long-distance axon regeneration in vivo through single-gene manipulation remains challenging. Nevertheless, combined multi-gene therapies have proven effective in significantly enhancing axonal regeneration. At present, research on promoting optic nerve regeneration remains slow, with most studies unable to achieve axonal growth beyond the optic chiasm or reestablish connections with the brain. Future research priorities include directing axonal growth along correct pathways, facilitating synapse formation and myelination, and modifying the inhibitory microenvironment. These strategies are crucial not only for optic nerve regeneration but also for broader applications in central nervous system repair. In this review, we discuss multifactors therapeutic strategies for optic nerve regeneration, offering insights into advancing nerve regeneration research.